Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
NCT03149575
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
Phase: Phase 3
Role: Lead Sponsor
Start: Oct 27, 2017
Completion: Aug 31, 2019
NCT03281681
A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer
Phase: Phase 1/2
Start: Mar 31, 2021
Completion: Sep 30, 2022